Shopping Cart
- Remove All
- Your shopping cart is currently empty
Murlentamab (GM102) is a humanized anti-AMhRII antibody. Murlentama has potential antitumor activity that induces macrophage-mediated antitumor-dependent cell-mediated cytotoxic effects (ADCC). Murl can stimulate the pro-inflammatory and anti-tumor internal environment by recruiting, collecting and activating T cells. Murlentama exerts antitumor activity by promoting naive macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $169 | In Stock | |
5 mg | $448 | In Stock | |
10 mg | $695 | In Stock | |
25 mg | $1,060 | In Stock | |
50 mg | $1,430 | In Stock |
Description | Murlentamab (GM102) is a humanized anti-AMhRII antibody. Murlentama has potential antitumor activity that induces macrophage-mediated antitumor-dependent cell-mediated cytotoxic effects (ADCC). Murl can stimulate the pro-inflammatory and anti-tumor internal environment by recruiting, collecting and activating T cells. Murlentama exerts antitumor activity by promoting naive macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming. |
In vivo | In vivo, Murlentamab (20 mg/kg; intravenous injection; twice a week; for 4 weeks) inhibits tumor growth in a mouse liver cancer patient-derived xenograft (PDX) model[2]. |
Alias | GM102, 3C23K |
Molecular Weight | 144.56 kDa |
Cas No. | 2058047-65-5 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.